ESSA Pharma Inc. (EPIX) Financials
Newest figures come from the 10-Q for Q3 FY2025, filed Aug 13, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the EPIX SEC filings page.
This page shows ESSA Pharma Inc. (EPIX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
ESSA Pharma Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
ESSA Pharma Inc. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
ESSA Pharma Inc. reported a net loss of $28.5M while operations used $22.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
ESSA Pharma Inc. reported -$4.0M in net income in Q3 2025. This represents an increase of 44.7% from the same quarter a year earlier. Against the prior quarter it is up 37.2%.
ESSA Pharma Inc. earned -$0.09 per diluted share (EPS) in Q3 2025. This represents an increase of 43.8% from the same quarter a year earlier. Against the prior quarter it is up 35.7%.
Not reported for Q3 2025.
Not reported for Q3 2025.
Cash & Balance Sheet
ESSA Pharma Inc. held $86.0M in cash as of Q3 2025; long-term debt is not reported for that period.
Not reported for Q3 2025.
Not reported for Q3 2025.
Margins & Returns
ESSA Pharma Inc.'s ROE was -3.7% in Q3 2025, measuring profit generated per dollar of shareholder equity. This is up 1.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.9 percentage points.
Not reported for Q3 2025.
Not reported for Q3 2025.
Not reported for Q3 2025.
Capital Allocation
None of these metrics is reported for Q3 2025.
EPIX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-Q | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | N/A | $3.5M-43.6% | $5.5M+1.8% | N/A | $5.5M-12.9% | $6.2M+37.9% | $5.4M+0.6% | N/A |
| SG&A Expenses | $5.4M+71.0% | $3.9M-9.7% | $4.2M+89.9% | N/A | $3.2M+20.3% | $4.3M+15.7% | $2.2M-12.0% | N/A |
| Net Income | -$4.0M+44.7% | -$6.4M+29.1% | -$8.5M-43.0% | N/A | -$7.2M+0.9% | -$9.0M-27.3% | -$6.0M+11.5% | N/A |
| EPS (Basic) | -$0.09+43.8% | -$0.14+30.0% | -$0.19-35.7% | -$0.14-16.7% | -$0.16+5.9% | -$0.20-25.0% | -$0.14+6.7% | -$0.12+20.0% |
| EPS (Diluted) | -$0.09+43.8% | -$0.14+30.0% | N/A | -$0.14-16.7% | -$0.16+5.9% | -$0.20-25.0% | -$0.14+6.7% | -$0.12+20.0% |
| Diluted Shares (Avg) | 44M+0.1% | 44M+0.3% | N/A | N/A | 44M+0.6% | 44M+0.3% | 44M+0.1% | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Operating Income, EBITDA, Interest Expense, Income Tax.
EPIX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-Q | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $110.5M-16.7% | $115.4M-16.3% | $122.6M-15.1% | $128.1M-14.1% | $132.7M-13.7% | $137.9M-13.0% | $144.5M-12.4% | $149.1M-12.0% |
| Current Assets | $110.5M-16.3% | $115.2M-16.1% | $122.1M-15.1% | $127.6M-14.3% | $132.1M-13.8% | $137.3M-13.2% | $143.9M-12.6% | $148.8M-12.0% |
| Cash & Equivalents | $86.0M0.0% | $86.3M-5.9% | $93.3M+164.0% | $103.7M+207.7% | $86.0M+123.5% | $91.7M+107.0% | $35.3M-31.0% | $33.7M-41.0% |
| Short-Term Investments | $23.7M-47.1% | $27.6M-37.6% | $27.2M-74.5% | $23.1M-79.8% | $44.7M-60.8% | $44.2M-60.8% | $106.8M-4.5% | $114.4M+3.8% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $1.6M-57.9% | $1.9M-57.8% | $3.9M+1.6% | $3.5M+0.3% | $3.8M+11.7% | $4.4M+104.4% | $3.8M+27.6% | $3.5M+46.4% |
| Current Liabilities | $1.6M-55.2% | $1.7M-58.9% | $3.7M+4.4% | $3.3M-5.6% | $3.6M+4.9% | $4.2M+94.5% | $3.5M+20.3% | $3.5M+51.3% |
| Non-Current Liabilities | $0-100.0% | $154K-39.0% | $180K-34.6% | $205K | $230K | $253K+1179.3% | $275K+470.6% | $0-100.0% |
| Total Equity | $108.9M-15.5% | $113.5M-14.9% | $118.8M-15.6% | $124.6M-14.4% | $128.9M-14.2% | $133.5M-14.6% | $140.7M-13.2% | $145.6M-12.9% |
| Retained Earnings | -$226.9M-12.5% | -$222.9M-14.7% | -$216.5M-16.8% | -$208.0M-15.9% | -$201.6M-15.9% | -$194.4M-16.6% | -$185.4M-16.2% | -$179.5M-17.4% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
EPIX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-Q | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.2M+26.9% | -$6.8M-0.5% | -$6.5M+4.7% | -$3.4M+25.0% | -$5.7M-17.1% | -$6.8M-13.4% | -$6.8M-55.1% | -$4.5M+40.0% |
| Stock-Based Compensation | N/A | N/A | $2.7M+236.3% | N/A | N/A | N/A | $803K-48.6% | N/A |
| Investing Cash Flow | $3.8M+16268.2% | -$154K-100.2% | -$3.9M-147.7% | $21.0M+8044.2% | $23K+102.6% | $62.5M+7226.0% | $8.2M+651.0% | -$265K+92.1% |
| Financing Cash Flow | $0-100.0% | $0-100.0% | $0-100.0% | $60K+537.2% | $26K+172.0% | $644K+1958.0% | $197K+1156.4% | -$14K+60.6% |
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
EPIX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-Q | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -3.7%+1.9pp | -5.6%+1.1pp | -7.2%-2.9pp | N/A | -5.6%-0.8pp | -6.7%-2.2pp | -4.2%-0.1pp | N/A |
| Return on Assets | -3.6%+1.8pp | -5.5%+1.0pp | -7.0%-2.8pp | N/A | -5.5%-0.7pp | -6.5%-2.1pp | -4.1%0.0pp | N/A |
| Current Ratio | 69.07+32.1x | 67.17+34.3x | 33.12-7.6x | 38.64-3.9x | 36.95-8.0x | 32.89-40.8x | 40.75-15.3x | 42.57-30.6x |
| Debt-to-Equity | 0.010.0x | 0.020.0x | 0.030.0x | 0.030.0x | 0.030.0x | 0.030.0x | 0.030.0x | 0.020.0x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| ESSA Pharma Inc. EPIX | FY2024 | N/A | -$28.5M | N/A | $9.5M | — |
| Cyclacel Phar Pr CYCCP | FY2025 | $747K | $3.0M | N/A | $9.6M | — |
| In8Bio, Inc. INAB | FY2025 | N/A | -$19.4M | N/A | $10.8M | — |
| Transcode Therapeutics Inc RNAZ | FY2025 | N/A | -$34.7M | N/A | $1.8M | — |
| Processa Pharmaceuticals Inc PCSA | FY2025 | N/A | $13.6M | N/A | $5.2M | — |
| Moleculin Biotec MBRX | FY2025 | $0 | $33.6M | N/A | $16.2M | — |
Where ESSA Pharma Inc. Ranks
Frequently Asked Questions
Is ESSA Pharma Inc. profitable?
No, ESSA Pharma Inc. (EPIX) reported a net income of -$28.5M in fiscal year 2024.
What is ESSA Pharma Inc.'s return on equity (ROE)?
ESSA Pharma Inc. (EPIX) has a return on equity of -22.9% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is ESSA Pharma Inc.'s operating cash flow?
ESSA Pharma Inc. (EPIX) recorded an outflow of $22.7M in operating cash flow during fiscal year 2024, representing cash used by core business activities.
What are ESSA Pharma Inc.'s total assets?
ESSA Pharma Inc. (EPIX) had $128.1M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does ESSA Pharma Inc. spend on research and development?
ESSA Pharma Inc. (EPIX) invested $21.2M in research and development during fiscal year 2024.
What is ESSA Pharma Inc.'s current ratio?
ESSA Pharma Inc. (EPIX) had a current ratio of 38.64 as of fiscal year 2024, which is generally considered healthy.
What is ESSA Pharma Inc.'s debt-to-equity ratio?
ESSA Pharma Inc. (EPIX) had a debt-to-equity ratio of 0.03 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is ESSA Pharma Inc.'s return on assets (ROA)?
ESSA Pharma Inc. (EPIX) had a return on assets of -22.3% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
How does ESSA Pharma Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2024, ESSA Pharma Inc. (EPIX) held $126.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $22.7M over that year. Dividing the one by the other, the reported balance equals about 67 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is ESSA Pharma Inc.'s Piotroski F-Score?
ESSA Pharma Inc. (EPIX) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are ESSA Pharma Inc.'s earnings high quality?
ESSA Pharma Inc. (EPIX) reported a net loss of $28.5M while operations used $22.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.